Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,310.00-3.52%ETH$2,383.44-3.86%GOLD$4,042.40-0.44%OIL$98.99-0.48%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBOT

Microbot Medical Inc.

Healthcare · Medical - Instruments & Supplies

$0.94

Up+$0.00 (+0.19%)

Updated Oct 22, 2026, 11:11 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
108.69M
P/E ratio
-12.46
Dividend yield
0.00%
52-week range
$0.93 – $2.86
Volume
485.26K
Avg. volume
3.35M

Price performance · MBOT

MBOT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

MBOT closed at $0.94 after 21 trading sessions, down 28.24% for the selected period.

Last close
$0.94
Period change
-28.24%
Period low
$0.94
Period high
$1.31
Daily close
View OHLC price history
MBOT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$0.98$0.9802$0.94$0.9401485.26K
Oct 20, 2026$0.9583$1.0299$0.945$0.9475725.29K
Oct 19, 2026$0.95$0.973$0.944$0.9528389.48K
Oct 16, 2026$0.955$0.9996$0.945$0.95803K
Oct 15, 2026$0.98$0.99$0.93$0.951.41M
Oct 14, 2026$1.01$1.03$0.99$0.9915568.19K
Oct 13, 2026$1.03$1.0387$1.005$1.02384.97K
Oct 12, 2026$1.07$1.08$1.03$1.04423.58K
Oct 9, 2026$1.08$1.085$1.05$1.07637.7K
Oct 8, 2026$1.12$1.15$1.06$1.07564.62K
Oct 7, 2026$1.08$1.16$1.07$1.12649.76K
Oct 6, 2026$1.09$1.165$1.05$1.071.99M
Oct 5, 2026$1.15$1.16$1.05$1.071.91M
Oct 2, 2026$1.23$1.23$1.14$1.16852.4K
Oct 1, 2026$1.21$1.23$1.18$1.20685.51K
Sep 30, 2026$1.25$1.2595$1.20$1.20518.81K
Sep 29, 2026$1.27$1.28$1.22$1.245631.35K
Sep 28, 2026$1.27$1.28$1.24$1.25424.65K
Sep 25, 2026$1.32$1.33$1.26$1.275485.33K
Sep 24, 2026$1.30$1.32$1.29$1.31310.5K
Sep 23, 2026$1.39$1.39$1.31$1.31461.01K

Latest MBOT news

The latest Smart Investors Daily articles mentioning MBOT.

Stock researchCompany · Overview

MBOT research

Overview

Company profile and research snapshot.

Company profile

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
MBOT recent ratings
DateFirmRatingTarget
Oct 21, 2026HC Wainwright & Co.Buy—
Aug 14, 2026B. Riley SecuritiesBuy—
Jun 3, 2026LUCID CAPITAL MARKETSBuy—
Apr 14, 2026HC Wainwright & Co.Buy—
Feb 10, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 4, 2026

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for he

Yahoo · Mar 3, 2026

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner re

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By